Drug Reimbursement, Biologics Exclusivity Should Be Part Of EU Trade Talks, PhRMA And BIO Say
Branded drug industry representatives presented a number of recommendations for U.S. negotiating priorities in upcoming trade talks with the European Union at a May 30 public hearing.
You may also be interested in...
Efforts to get a major new trade bloc to adopt stronger pharmaceutical intellectual property rules, including a potential path breaking agreement on biologics data exclusivity remains a work-in-progress, trade negotiators said at the end of the 18th round of the Trans-Pacific Partnership talks. But hope still floats the diverse group of 12 countries might find compromise language.
Trans-Pacific Partnership Pact Set As Test Ground For Getting Biologics Data Exclusivity At National Levels
While much of the talk on data exclusivity for biologics in the Trans-Pacific Partnership has been on the 12-year window in U.S. law, sources said current thinking is to get the other nations to agree to approve their own standards within a set time frame and use it as a template for future free trade agreements.
NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.